Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)

I D Cameron; S Robinovitch; S Birge; P Kannus; K Khan; J Lauritzen; J Howland; S Evans; J Minns; A Laing; P Cripton; S Derler; D Plant; D P Kiel

doi:http://dx.doi.org/10.1007/s00198-009-1055-2

Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)

I D Cameron, S Robinovitch, S Birge, P Kannus, K Khan, J Lauritzen, J Howland, S Evans, J Minns, A Laing, P Cripton, S Derler, D Plant, D P Kiel

28 Citations (Scopus)

Abstract

Introduction: While hip protectors are effective in some clinical trials, many, including all in community settings, have been unable to demonstrate effectiveness. This is due partly to differences in the design and analysis. The aim of this report is to develop recommendations for subsequent clinical research. Methods: In November of 2007, the International Hip Protector Research Group met to address barriers to the clinical effectiveness of hip protectors. This paper represents a consensus statement from the group on recommended methods for conducting future clinical trials of hip protectors. Results and conclusions: Consensus recommendations include the following: The use of a hip protector that has undergone adequate biomechanical testing, the use of sham hip protectors, the conduct of clinical trials in populations with annual hip fracture incidence of at least 3%, a run-in period with demonstration of adequate adherence, surveillance of falls and adherence, and the inclusion of economic analyses. Larger and more costly clinical trials are required to definitively investigate effectiveness of hip protectors.

Original language	English
Journal	Osteoporosis International
Volume	21
Issue number	1
Pages (from-to)	1-10
Number of pages	10
ISSN	0937-941X
DOIs	https://doi.org/10.1007/s00198-009-1055-2
Publication status	Published - 1 Jan 2010

Access to Document

http://dx.doi.org/10.1007/s00198-009-1055-2

Cite this

Cameron, I. D., Robinovitch, S., Birge, S., Kannus, P., Khan, K., Lauritzen, J., Howland, J., Evans, S., Minns, J., Laing, A., Cripton, P., Derler, S., Plant, D., & Kiel, D. P. (2010). Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II). Osteoporosis International, 21(1), 1-10. https://doi.org/10.1007/s00198-009-1055-2

Cameron, ID, Robinovitch, S, Birge, S, Kannus, P, Khan, K, Lauritzen, J, Howland, J, Evans, S, Minns, J, Laing, A, Cripton, P, Derler, S, Plant, D & Kiel, DP 2010, 'Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)', Osteoporosis International, vol. 21, no. 1, pp. 1-10. https://doi.org/10.1007/s00198-009-1055-2

@article{b7f743ae28574251b1abd2fd3023d6fe,

title = "Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)",

abstract = "Introduction: While hip protectors are effective in some clinical trials, many, including all in community settings, have been unable to demonstrate effectiveness. This is due partly to differences in the design and analysis. The aim of this report is to develop recommendations for subsequent clinical research. Methods: In November of 2007, the International Hip Protector Research Group met to address barriers to the clinical effectiveness of hip protectors. This paper represents a consensus statement from the group on recommended methods for conducting future clinical trials of hip protectors. Results and conclusions: Consensus recommendations include the following: The use of a hip protector that has undergone adequate biomechanical testing, the use of sham hip protectors, the conduct of clinical trials in populations with annual hip fracture incidence of at least 3%, a run-in period with demonstration of adequate adherence, surveillance of falls and adherence, and the inclusion of economic analyses. Larger and more costly clinical trials are required to definitively investigate effectiveness of hip protectors.",

author = "Cameron, {I D} and S Robinovitch and S Birge and P Kannus and K Khan and J Lauritzen and J Howland and S Evans and J Minns and A Laing and P Cripton and S Derler and D Plant and Kiel, {D P}",

year = "2010",

month = jan,

day = "1",

doi = "http://dx.doi.org/10.1007/s00198-009-1055-2",

language = "English",

volume = "21",

pages = "1--10",

journal = "Osteoporosis International",

issn = "0937-941X",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)

AU - Cameron, I D

AU - Robinovitch, S

AU - Birge, S

AU - Kannus, P

AU - Khan, K

AU - Lauritzen, J

AU - Howland, J

AU - Evans, S

AU - Minns, J

AU - Laing, A

AU - Cripton, P

AU - Derler, S

AU - Plant, D

AU - Kiel, D P

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction: While hip protectors are effective in some clinical trials, many, including all in community settings, have been unable to demonstrate effectiveness. This is due partly to differences in the design and analysis. The aim of this report is to develop recommendations for subsequent clinical research. Methods: In November of 2007, the International Hip Protector Research Group met to address barriers to the clinical effectiveness of hip protectors. This paper represents a consensus statement from the group on recommended methods for conducting future clinical trials of hip protectors. Results and conclusions: Consensus recommendations include the following: The use of a hip protector that has undergone adequate biomechanical testing, the use of sham hip protectors, the conduct of clinical trials in populations with annual hip fracture incidence of at least 3%, a run-in period with demonstration of adequate adherence, surveillance of falls and adherence, and the inclusion of economic analyses. Larger and more costly clinical trials are required to definitively investigate effectiveness of hip protectors.

AB - Introduction: While hip protectors are effective in some clinical trials, many, including all in community settings, have been unable to demonstrate effectiveness. This is due partly to differences in the design and analysis. The aim of this report is to develop recommendations for subsequent clinical research. Methods: In November of 2007, the International Hip Protector Research Group met to address barriers to the clinical effectiveness of hip protectors. This paper represents a consensus statement from the group on recommended methods for conducting future clinical trials of hip protectors. Results and conclusions: Consensus recommendations include the following: The use of a hip protector that has undergone adequate biomechanical testing, the use of sham hip protectors, the conduct of clinical trials in populations with annual hip fracture incidence of at least 3%, a run-in period with demonstration of adequate adherence, surveillance of falls and adherence, and the inclusion of economic analyses. Larger and more costly clinical trials are required to definitively investigate effectiveness of hip protectors.

U2 - http://dx.doi.org/10.1007/s00198-009-1055-2

DO - http://dx.doi.org/10.1007/s00198-009-1055-2

M3 - Journal article

SN - 0937-941X

VL - 21

SP - 1

EP - 10

JO - Osteoporosis International

JF - Osteoporosis International

IS - 1

ER -

Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)

Abstract

Access to Document

Fingerprint

Cite this